University of Nebraska
Welcome,         Profile    Billing    Logout  
 47 Trials 
53 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Vose, Julie M
BRUIN-MCL-321, NCT04662255 / 2020-004553-72: Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

Active, not recruiting
3
500
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa
Loxo Oncology, Inc., Eli Lilly and Company
Lymphoma, Mantle-Cell
12/25
07/26
SYMPHONY-1, NCT04224493 / 2019-003333-42: A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

Hourglass Jan 2023 - Dec 2023 : First interim futility data from P3 portion of P1b/3 SYMPHONY-1 trial in combination with Rituxan for relapsed/refractory follicular lymphoma
Jan 2023 - Dec 2023: DOR/PFS data from P1b portion of P1b/3 SYMPHONY-1 trial in combination with Revlimid and Rituxan for relapsed/refractory follicular lymphoma
Hourglass Jan 2022 - Dec 2022 : Completion of enrollment of P3 portion of P1b/3 trial for r/r follicular lymphoma
Checkmark Data from SYMPHONY-1 trial in combination with Rituxan and Revlimid for follicular lymphoma
Jun 2022 - Jun 2022: Data from SYMPHONY-1 trial in combination with Rituxan and Revlimid for follicular lymphoma
More
Recruiting
3
612
Europe, Canada, US, RoW
Tazemetostat, EPZ-6438, IPN60200, Placebo oral tablet, Lenalidomide, Rituximab
Epizyme, Inc.
Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma
03/26
03/29
TRANSCEND-CLL-004, NCT03331198: Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Checkmark Data from TRANSCEND-CLL-004 trial for r/r CLL or SLL
Jan 2023 - Jan 2023: Data from TRANSCEND-CLL-004 trial for r/r CLL or SLL
Checkmark From TRANSCEND-CLL-004 trial in CLL at ASH 2019
Dec 2019 - Dec 2019: From TRANSCEND-CLL-004 trial in CLL at ASH 2019
Hourglass Oct 2018 - Dec 2018 : Completion of enrollment in P2 TRANSCEND WORLD trial for 3L DLBCL
More
Recruiting
1/2
320
Canada, US
JCAR017 (lisocabtagene maraleucel), JCAR017 (lisocabtagene maraleucel) + ibrutinib, JCAR017 (lisocabtagene maraleucel) + venetoclax
Juno Therapeutics, a Subsidiary of Celgene
Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic
11/27
11/27
SGN35C-001, NCT06254495: A Safety Study of SGN-35C in Adults With Advanced Cancers

Recruiting
1
170
Europe, US
SGN-35C
Seagen Inc.
Hodgkin Disease, Lymphoma, T-Cell, Peripheral, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic
02/28
08/28
Desouza, Cyrus
QWINT-1, NCT05662332: A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time

Completed
3
795
US, RoW
Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Glargine
Eli Lilly and Company
Type 2 Diabetes, T2D
07/24
07/24
Rochling, Fedja
NCT04950127 / 2021-000007-21: Global Linerixibat Itch Study of Efficacy and Safety in Primary Biliary Cholangitis (PBC) (GLISTEN)

Active, not recruiting
3
238
Europe, Canada, Japan, US, RoW
Linerixibat, Placebo
GlaxoSmithKline
Pruritus
10/24
01/25
LLSAT, NCT04167358 / 2019-003158-10: Linerixibat Long-term Safety, and Tolerability Study

Recruiting
3
251
Europe, Canada, Japan, US, RoW
Linerixibat
GlaxoSmithKline, GlaxoSmithKline LLC, GlaxoSmithKline Research & Development Limited
Cholestasis
02/27
02/27
Poole, Jill A
NIMBLE, NCT04718389 / 2020-003612-28: A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype

Hourglass Feb 2024 - Jun 2024 : Acceptance of regulatory submission in China for CRSwNP
Active, not recruiting
3
1667
Europe, Canada, Japan, US, RoW
GSK3511294 (Depemokimab), Mepolizumab, Benralizumab, Placebo, Standard of care (SoC), Pre-filled Syringes (PFS)
GlaxoSmithKline, Iqvia Pty Ltd
Asthma
10/25
10/25
Aizenberg, Michele
NCT04222062: A Study Comparing GLIADEL to Stereotactic Radiosurgery in Metastatic Brain Disease

Recruiting
2
100
US
Carmustine 7.7Mg Wafer, GLIADEL
University of Nebraska, Arbor Pharmaceuticals, Inc.
Brain Tumor - Metastatic
12/25
12/26
NCT04427384: Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)

Recruiting
N/A
600
US
GammaTile
GT Medical Technologies, Inc.
Brain Tumor, Recurrent, Brain Tumor, Brain Tumor, Primary, Brain Tumor - Metastatic, Brain Tumor, Adult: Glioblastoma, Brain Tumor, Adult Meningioma
10/28
12/28
Yetman, Angela
FUEL-2, NCT05918211: Fontan Udenafil Exercise Longitudinal Assessment Trial - 2

Recruiting
3
436
US, RoW
Udenafil, Placebo
Mezzion Pharma Co. Ltd
Single Ventricle Heart Disease
10/25
10/25
Shah, Mitesh
GESTALT, NCT05342883: GammaTile and Stupp in Newly Diagnosed GBM

Recruiting
4
61
US
Surgical tumor resection, GammaTile radiation therapy implantation, Stupp protocol (EBRT and Temozolamide)
GT Medical Technologies, Inc.
Glioblastoma
07/27
12/27
ROADS, NCT04365374: Post-Surgical Stereotactic Radiotherapy (SRT) Versus GammaTile- (Radiation One and Done Study)

Recruiting
3
180
US
Gamma Tile-Surgically Targeted Radiation Therapy (STaRT), Carrier Tile Brachytherapy Therapy (CTBT), Stereotactic Radiation Therapy
GT Medical Technologies, Inc.
Brain Metastases
12/25
12/27
NCT04427384: Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)

Recruiting
N/A
600
US
GammaTile
GT Medical Technologies, Inc.
Brain Tumor, Recurrent, Brain Tumor, Brain Tumor, Primary, Brain Tumor - Metastatic, Brain Tumor, Adult: Glioblastoma, Brain Tumor, Adult Meningioma
10/28
12/28
Lunning, Matthew
DALY II USA, NCT04792489: / MB-CART2019.1 for DLBCL

Recruiting
2
110
US
zamtocabtagene autoleucel (MB-CART2019.1), Cyclophosphamide, Fludarabine, Bendamustine
Miltenyi Biomedicine GmbH
Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B Cell Lymphoma, High Grade B-cell Lymphoma (HGBCL), Primary Mediastinal B-cell Lymphoma (PMBCL), Transformed Lymphoma, Central Nervous System Lymphoma
12/24
12/26
UPCC 48420, NCT04889716: CAR-T Followed by Bispecific Antibodies

Recruiting
2
42
US
mosunetuzumab, RO7030816, BTCT4465A, Lunsumio, glofitamab, CD20 TCB, RO7082859, obinutuzumab, Gazyva, Gazyvaro, RO5072759, huMAb , GA101
Abramson Cancer Center at Penn Medicine, Genentech, Inc.
Large B-cell Lymphoma, DLBCL - Diffuse Large B Cell Lymphoma
12/24
12/25
IMAGINE, NCT05138458: A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL

Suspended
1/2
40
US
MT-101, MT-101 + Conditioning (Lymphodepleting) Chemotherapy
Myeloid Therapeutics
Lymphoma, T-Cell, Peripheral, Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides, Adoptive Cellular Immunotherapy, Cell Therapy
11/24
10/25
ARDENT, NCT05878184: Study Evaluating SC291 in Subjects With r/r B-cell Malignancies

Active, not recruiting
1
16
US, RoW
SC291, Cyclophosphamide, Fludarabine
Sana Biotechnology
Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
11/25
11/38
Feloney, Michael
NCT04248283: Adjustable Continence Therapy (ACT) for the Treatment of Female SUI

Recruiting
N/A
167
US
Adjustable Continence Therapy for Women (ACT)
Uromedica
Urinary Incontinence, Urinary Incontinence,Stress
09/25
12/25
Lowes, Brian D
NCT03644667: Tocilizumab in Cardiac Transplantation

Active, not recruiting
2
385
US
tocilizumab, Actemra®, Placebo, Placebo for tocilizumab, Placebo for Actemra®, Standard of Care Triple IS, calcineurin inhibitor: (tacrolimus (Prograf ®)), anti-proliferative treatment: (mycophenolate mofetil ),, MMF, CellCept®, Myfortic®, enteric-coated mycophenolate sodium, steroids: methylprednisolone/prednisone
National Institute of Allergy and Infectious Diseases (NIAID), PPD
Heart Transplant
04/25
04/25
Gundabolu, Krishna
FELIX, NCT04404660: A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)

Hourglass Jul 2024 - Dec 2024 : Submission in UK for adult r/r B-ALL
Active, not recruiting
1/2
153
NA
AUTO1, Obecabtagene autoleucel (obe-cel)
Autolus Limited
Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
05/25
05/25
Florescu, Diana
NCT03924219: CMV T Cell Immunity in Pediatric Solid Organ Transplant Recipients

Active, not recruiting
N/A
120
US
CMV T cell Immunity Assay
Vanderbilt University Medical Center, ViraCor Laboratories
Heart Transplant Infection, Kidney Transplant Infection, Liver Transplant Infection, CMV
08/24
07/25
Fayad, Pierre
CAPTIVA, NCT05047172: Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis

Recruiting
3
1683
US
Ticagrelor + Aspirin, Brilinta, Rivaroxaban + Aspirin, Xarelto, Clopidogrel + Aspirin, Plavix, Risk Factor Management
University of Florida, National Institute of Neurological Disorders and Stroke (NINDS), University of Cincinnati, Medical University of South Carolina, Janssen Scientific Affairs, LLC, AstraZeneca
Intracranial Arteriosclerosis, Stroke
05/28
05/28
Blumel, Susan
IMAGINE, NCT05138458: A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL

Suspended
1/2
40
US
MT-101, MT-101 + Conditioning (Lymphodepleting) Chemotherapy
Myeloid Therapeutics
Lymphoma, T-Cell, Peripheral, Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides, Adoptive Cellular Immunotherapy, Cell Therapy
11/24
10/25
ARDENT, NCT05878184: Study Evaluating SC291 in Subjects With r/r B-cell Malignancies

Active, not recruiting
1
16
US, RoW
SC291, Cyclophosphamide, Fludarabine
Sana Biotechnology
Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
11/25
11/38
Teply, Benjamin A
KEYNOTE-D74, NCT05911295: Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

Recruiting
3
400
Europe, Canada, US, RoW
disitamab vedotin, RC48, RC48-ADC, pembrolizumab, KEYTRUDA®, gemcitabine, Gemzar, cisplatin, carboplatin
Seagen Inc., RemeGen Co., Ltd., Merck Sharp & Dohme LLC
Urothelial Carcinoma
06/26
04/29
NCT03047135: Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis

Active, not recruiting
2
51
US
Olaparib
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, AstraZeneca
Prostate
05/23
05/25
NCT02744287: Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors

Feb 2023 - Feb 2023: Early P1 data in patients with metastatic castration-resistant prostate cancer at ASCO-GU 2023
Checkmark Updated data from BP-012 trial
Oct 2020 - Oct 2020: Updated data from BP-012 trial
Checkmark From BP-012 trial in advanced solid tumors at ASCO 2019 [screenshot]
May 2019 - Jun 2019: From BP-012 trial in advanced solid tumors at ASCO 2019 [screenshot]
More
Suspended
1/2
151
US
BPX-601, Rimiducid, AP1903
Bellicum Pharmaceuticals
Metastatic Castration-resistant Prostate Cancer, Metastatic Prostate Cancer
10/25
02/26
Goldsweig, Andrew
NCT02661451: Transcatheter Aortic Valve Replacement to UNload the Left Ventricle in Patients With ADvanced Heart Failure (TAVR UNLOAD)

Active, not recruiting
N/A
178
Europe, Canada, US
SAPIEN 3 THV, Optimal Heart Failure Therapy
Cardiovascular Research Foundation, New York, Cardialysis BV, Avania
Aortic Valve Stenosis
02/23
02/25
NCT05069558: Comparing PFO Outcomes of the Occlutech Flex II PFO Occluder to Standard of Care PFO Occlusion

Active, not recruiting
N/A
450
Europe, Canada, US
Investigational PFO Closure Device, Standard of Care PFO Closure Device
Occlutech International AB
Stroke, Patent Foramen Ovale, PFO
11/25
10/26
Siddique, Aleem
NCT03639025: OCS™ Lung TOP Registry For Donor Lungs for Transplantation

Active, not recruiting
N/A
458
US
OCS Lung System
TransMedics
Lung Transplantation
11/25
11/29
Johnson, Taylor
VENTURE, NCT06068946: VK2735 for Weight Management Phase 2

Active, not recruiting
2
176
US
VK2735, Placebo
Viking Therapeutics, Inc.
Weight Loss
02/24
06/24
DETECT-HF, NCT06378632: AN INTERNATIONAL, OBSERVATIONAL, BLINDED STUDY TO ASSESS THE PERFORMANCE OF THE CORDIO HEARO SYSTEM

Recruiting
N/A
500
Europe, US, RoW
Hearo App
Cordio Medical
Heart Failure
01/25
03/25
NCT02907398: Adherence and Outcome of Upper Airway Stimulation (UAS) for OSA International Registry

Active, not recruiting
N/A
5000
Europe, US
Inspire therapy, ADHERE, No intervention, CONTROL
Inspire Medical Systems, Inc.
Obstructive Sleep Apnea
09/25
12/25
Klute, Kelsey A
CA209-76L, NCT04021108: Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol )

Active, not recruiting
2
80
US
Nivolumab 240 MG
Weill Medical College of Cornell University, Bristol-Myers Squibb
Gastroesophageal Adenocarcinoma
04/25
04/26
NCT05630183: A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer

Hourglass Jan 2024 - Jun 2024 : Results from C-800-22 trial for 2L metastatic pancreatic cancer
Recruiting
2
78
US
Botensilimab, AGEN1181, Gemcitabine, Nab-paclitaxel
Agenus Inc.
Metastatic Pancreatic Ductal Adenocarcinoma
12/24
12/24
NCT05494697: Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC

Hourglass Jan 2024 - Dec 2024 : Data readout for locally advanced pancreatic adenocarcinoma
Recruiting
2
90
US
Rintatolimod, Ampligen, poly I : poly C12U
AIM ImmunoTech Inc., Amarex Clinical Research
Pancreatic Cancer
09/28
10/28
Bares, Sara
B-HASTE, NCT04249037: Rapid Start vs. Standard Start Antiretroviral Therapy (ART) in HIV

Terminated
4
10
US
bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF), Biktarvy, Standard initiation of antiretroviral therapy (ART), Standard of Care ART
University of Colorado, Denver, Gilead Sciences
HIV/AIDS
07/23
07/23
STOMP, NCT05534984: Study of Tecovirimat for Human Mpox Virus

Active, not recruiting
3
719
Japan, US, RoW
Tecovirimat Oral Capsule, Placebo, Tecovirimat Oral Capsule (Open Label)
National Institute of Allergy and Infectious Diseases (NIAID), SIGA Technologies
MPOX
10/24
09/25
VOLITION, NCT05917509: A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy

Active, not recruiting
3
171
Europe, Canada, US, RoW
DTG/3TC, Dovato, Cabotegravir (CAB) LA, Vocabria, Rilpivirine (RPV) LA, Rekambys
ViiV Healthcare, GlaxoSmithKline, PPD DEVELOPMENT, LP
HIV Infections
10/25
10/26
Westphal, Scott
ProActive, NCT04091984: The PROspera Kidney Transplant ACTIVE Rejection Assessment Registry

Active, not recruiting
N/A
5000
US
Prospera
Natera, Inc., University of Maryland
Kidney Transplant Rejection
10/26
10/27
Hardiman, Penny
FELIX, NCT04404660: A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)

Hourglass Jul 2024 - Dec 2024 : Submission in UK for adult r/r B-ALL
Active, not recruiting
1/2
153
NA
AUTO1, Obecabtagene autoleucel (obe-cel)
Autolus Limited
Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
05/25
05/25
Shah, Kushal
NCT04427384: Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)

Recruiting
N/A
600
US
GammaTile
GT Medical Technologies, Inc.
Brain Tumor, Recurrent, Brain Tumor, Brain Tumor, Primary, Brain Tumor - Metastatic, Brain Tumor, Adult: Glioblastoma, Brain Tumor, Adult Meningioma
10/28
12/28
Gard, Andrew
STEM, NCT04410146: The SQUID Trial for the Embolization of the Middle Meningeal Artery for Treatment of Chronic Subdural Hematoma

Completed
N/A
310
Europe, US
SQUID Embolization, SQUID Embolization and Surgical Evacuation, Surgical Evacuation, Other: Medical Management
Balt USA, Balt Extrusion, Embo-Flüssigkeiten A.G., AXIOM Real Time Metrics
Subdural Hematoma, Chronic
02/24
05/24
Ravipati, Prasanth
REBOOT, NCT03949855: Belimumab With Rituximab for Primary Membranous Nephropathy

Recruiting
2
58
Canada, US
Belimumab, Benlysta®, Placebo for Belimumab, Belimumab placebo, Rituximab, Rituxan®
National Institute of Allergy and Infectious Diseases (NIAID), Immune Tolerance Network (ITN), GlaxoSmithKline, PPD DEVELOPMENT, LP, Rho Federal Systems Division, Inc.
Membranous Nephropathy, Nephrotic Syndrome
03/29
03/30
Platel, Molly
REBOOT, NCT03949855: Belimumab With Rituximab for Primary Membranous Nephropathy

Recruiting
2
58
Canada, US
Belimumab, Benlysta®, Placebo for Belimumab, Belimumab placebo, Rituximab, Rituxan®
National Institute of Allergy and Infectious Diseases (NIAID), Immune Tolerance Network (ITN), GlaxoSmithKline, PPD DEVELOPMENT, LP, Rho Federal Systems Division, Inc.
Membranous Nephropathy, Nephrotic Syndrome
03/29
03/30
Bandes, Miguel
REBOOT, NCT03949855: Belimumab With Rituximab for Primary Membranous Nephropathy

Recruiting
2
58
Canada, US
Belimumab, Benlysta®, Placebo for Belimumab, Belimumab placebo, Rituximab, Rituxan®
National Institute of Allergy and Infectious Diseases (NIAID), Immune Tolerance Network (ITN), GlaxoSmithKline, PPD DEVELOPMENT, LP, Rho Federal Systems Division, Inc.
Membranous Nephropathy, Nephrotic Syndrome
03/29
03/30
NCT04057352: Citadel Embolization Device Study

Recruiting
N/A
150
US
Citadel Embolization Device
Stryker Neurovascular
Unruptured Wide-neck Aneurysms
06/26
06/26
Hoover-Schultz, Barbara
stAAAble, NCT06001918: Nectero EAST System Clinical Study

Recruiting
2/3
400
US
Nectero EAST System
Nectero Medical, Inc.
Abdominal Aortic Aneurysm
03/27
12/29
NCT05820451: Impella Real-World Surveillance of Patients Using Sodium Bicarbonate

Completed
N/A
312
NA
Impella CP, 2.5, 5.0 and 5.5 with Sodium Bicarbonate used as purge solution, Impella RP with Sodium Bicarbonate used as purge solution
Abiomed Inc.
Cardiogenic Shock, High Risk PCI
02/24
02/24
Al-Kazaz, Mohammed
MAVERIC-2, NCT06708299: CardiolRx in Recurrent Pericarditis Following IL-1 Blocker Cessation

Not yet recruiting
3
110
US
CardiolRx, Pharmaceutically produced cannabidiol
Cardiol Therapeutics Inc.
Recurrent Pericarditis
06/26
07/26
RESONANCE, NCT04687358: REgiStry Of the NAtural History of recurreNt periCarditis in pEdiatric and Adult Patients

Recruiting
N/A
500
US
Kiniksa Pharmaceuticals International, plc, Kiniksa Pharmaceuticals (UK), Ltd.
Recurrent Pericarditis
02/26
02/26
McHatton, Heather
V-INCLUSION, NCT06249165: VictORION-INCLUSION: Evaluating Inclisiran for Cholesterol Managment in Heart Disease

Recruiting
4
1440
US
Inclisiran, Leqvio
Duke University, Novartis Pharmaceuticals
Atherosclerotic Cardiovascular Disease
08/26
08/27

Download Options